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Abstract 
Background—Post-stroke angiogenesis contributes to long-term recovery after stroke. Signal 
transducer and activator of transcription-3 (Stat3) is a key regulator for various inflammatory 
signals and angiogenesis. It was the aim of this study to determine its function in post stroke 
outcome. 
Methods and Results—We generated a tamoxifen-inducible and endothelial-specific Stat3 
knockout mouse model by crossbreeding Stat3floxed/KO and Tie2-CreERT2 mice. Cerebral ischemia 
was induced by 30 minutes of middle cerebral artery occlusion (MCAo). We demonstrated that 
endothelial Stat3 ablation did not alter lesion size 2 days after ischemia but did worsen functional 
outcome at 14 days and increase lesion size at 28 days. At this late time point vascular Stat3 
expression and phosphorylation were still increased in wildtype mice. Gene array analysis of a 
CD31-enriched cell population of the neurovascular niche showed that endothelial Stat3 ablation 
led to a shift toward an anti-angiogenic and axon growth-inhibiting micro-milieu after stroke, 
with an increased expression of Adamts9. Remodeling and glycosylation of the extracellular 
matrix (ECM) as well as microglia proliferation were increased while angiogenesis was reduced. 
Conclusions—Endothelial Stat3 regulates angiogenesis, axon growth and ECM-remodeling and 
is essential for long-term recovery after stroke. It might serve as a potent target for stroke 
treatment after the acute phase by fostering angiogenesis and neuroregeneration. 
Key words: cerebral ischemia, angiogenesis, inflammation, gene microarray, endothelial cell
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Introduction 
Long-term recovery after brain ischemia is linked to angiogenesis. How newly formed vessels 
can improve functional outcome is unclear. Angiogenesis restores oxygen and nutrient supply to 
the affected brain tissue, but post-stroke angiogenesis starts too late to interact with ischemic cell 
death cascades. The newly formed vessels seem to be more relevant for regenerative mechanisms 
such as neurogenesis, axonal growth and synaptic plasticity.1 Angiogenesis and neurogenesis are 
intricately linked.2 Axonal growth cones and endothelial tip cells of sprouting vessels share many 
features and respond to the same signaling pathways.3 Angiogenic vessels provide neurotrophic 
support to newly generated neurons and facilitate synaptogenesis.4  
Treatments are needed that foster regeneration at later time points. Strategies focusing on 
angiogenesis are ambivalent. Most angiogenic factors like vascular endothelial growth factor 
(Vegf) may increase vascular permeability and thus increase edema formation. In addition, 
angiogenesis is strongly related to inflammatory pathways. For instance, Vegf as well as 
Interleukin 6 (Il6) converge on the Signal Transducer and Activator of Transcription-3 (Stat3) 
signaling pathway; on the other hand activation of Stat3 by Il6 increases Vegf production.5 In 
endothelial cells Stat3 activation promotes angiogenesis by regulating endothelial cell migration 
and proliferation6 and is involved in vascular diseases such as pulmonary hypertension.7  
Stat3 shows neuroprotective properties in the acute phase of stroke, inhibiting apoptosis 
and scavenging reactive oxygen species (ROS) in neurons, thereby reducing infarct size.8,9,10, 
11,12,13 It might however induce detrimental effects in the sub-acute phase after stroke. It has been 
shown that Stat3 is mainly expressed and activated in microglia and macrophages 24-72 hours 
after cerebral ischemia.14 Blocking Stat3 phosphorylation within the first 72 hours reduced lesion 
size; this effect is mediated by an inactivation of Stat3 in microglia and macrophages.  
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Following brain ischemia, endothelial cells seem to express and phosphorylate Stat3 later 
than neurons and microglia, beginning at 48 hours and continuing for at least 7 days.8 This is the 
time window in which expression and phosphorylation of Stat3 by endothelial cells reach their 
highest levels compared to those of other cell types.8 This delayed activation of the angiogenic 
Stat3 pathway in endothelial cells after cerebral ischemia may indicate an important function of 
endothelial Stat3 in regenerative mechanisms. We previously demonstrated that lack of Il6 
increased lesion size and worsened functional outcome 28 days after ischemia. The underlying 
mechanism seemed to be a reduction of angiogenesis.15  
It was therefore the aim of this study to search for the specific role of endothelial Stat3 in 
the pathophysiology of cerebral ischemia and in particular its effects on post-stroke angiogenesis 
and long-term outcome. To obtain a knockout of Stat3 which is restricted to endothelial cells in
vivo, we used an inducible endothelial-specific Stat3 knockout mouse model by crossbreeding 
Stat3floxed/KO mice16 with Tie2-CreERT2 mice17 (endothelial-Tie2-CreERT2;Stat3floxed/KO). Tie2-
CreERT2 littermates treated with tamoxifen served as controls. Cerebral ischemia was induced by 
filamentous occlusion of the A. cerebri media for 30 min (MCAo). This study shows for the first 
time that endothelial Stat3 activation is necessary for post-stroke angiogenesis, alters long-term 
lesion size and plays a beneficial role in functional improvement after stroke. Endothelial loss of 
Stat3 leads to an anti-angiogenic and axon growth inhibiting micro-milieu within the 
neurovascular niche with induced Adamts9 expression and consequently an altered remodeling 
of the extracellular matrix. 
 
Methods
A detailed method section is provided in the Online Data Supplements. 
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Animals and treatments 
All animal experiments were approved by the local governmental authorities (Landesamt für 
Gesundheit und Soziales, G0354/11). Stat3floxed/KO mice16 were crossbred with Tie2-CreERT2 
mice17. Endothelial-specific knockout of Stat3 was induced by a 5 day i.p. application of 
tamoxifen (1 mg/d) 7 days prior to surgery. Tie2-CreERT2 littermates were treated with tamoxifen 
and served as a control group. In a total of 3 animals – two wildtype mice and 1 knockout animal 
– no lesions developed. These 3 animals were excluded from the study.  
Model of middle cerebral artery occlusion (MCAo) 
Filamentous middle cerebral artery occlusion of the left side was performed for 30 minutes with 
indicated reperfusion time points according to the published standard operating procedure in our 
laboratory18 in the DIN9001-certified laboratories of the Department of Experimental Neurology 
at the Charité.  
Real-time RT-PCR 
RNA from slices of ischemic and contralateral hemispheres was extracted using Trizol 
(Invitrogen). 1 μg of RNA was transcribed with MLV-reverse transcriptase (Promega). Real-
time PCR was performed with intron spanning primers for tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein (Ywhaz) and succinate 
dehydrogenase complex, subunit A, flavoprotein (Sdha) as internal controls19, and primers for 
Stat3 using Sybr green (Qiagen). Foldamount of mRNA compared to mean of internal controls 
was calculated using the equation: 2-(Ct(gene of interest)-Ct(internal control)) 
Histology and immunofluorescence 
Mice were placed under deep anesthesia, cardially perfused with NaCl-solution, and decapitated. 
The brains were snap frozen in -40 °C isopentane for cryostat sectioning 2 and 28 days after 
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MCAo. 20 μm cryosections were fixed with aceton/methanol and stained for caveolin-1, 
pStat3 (Tyr705), BrdU, NeuN, isolectin-B4, Adamts9. Cytospins after CD31 MACS were 
stained for caveolin-1. Orthogonal projections of vascular networks in the peri-infarct region 
were stained with isolectin-B4 (see online supplements for details).  
Lesion volume determination and functional outcome 
We quantified cerebral lesion volume with ImageJ analysis software (NIH, USA) on 20 μm 
NeuN-DAB-stained cryostat sections and calculated volume by summing up the infarct sizes of 
each section as previously described18 or by T2-weighted MRI imaging. Functional outcome was 
determined with behavioral tests (Rotarod test and the extended neuroscore). To determine lesion 
size we used a total of 16 endothelial-Tie2-CreERT2;Stat3floxed/KO and 23 Tie2-CreERT2 littermates. 
All underwent MRI at 2 days after ischemia. A subset of 9 endothelial-Tie2-CreERT2;Stat3floxed/KO 
and 12 Tie2-CreERT2 littermates was killed at 2 days after ischemia and a subset of 7 endothelial-
Tie2-CreERT2;Stat3floxed/KO and 11 Tie2-CreERT2 littermates at 28 days for histological lesion size 
determination. For behavioral tests 12 endothelial-Tie2-CreERT2;Stat3floxed/KO and 12 Tie2-CreERT2 
littermates were used. 
ELISA
ELISA assays for determining Vegf (R&D systems) and Il6 (Invitrogen) levels were performed 
according to manufacturer’s instructions. 
Isolation of CD31-enriched cells 
Mice were killed 4 days after cerebral ischemia. The ipsi- and contralateral hemispheres were 
divided and processed separately. Hemispheres from 7 animals were pooled. The tissue was 
dissociated using the Papain Neural Tissue Dissociation Kit (Miltenyi Biotec). Myelin was 
removed following a protocol published elsewhere.20 Cells were labeled with anti-CD31 
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microbeads™ (Miltenyi Biotec). We performed MACS isolation according to the manufacturer’s 
instructions. Total RNA from MACS was isolated using the RNeasy Plus Mini Kit (Qiagen). A 
total of 21 endothelial-Tie2-CreERT2;Stat3floxed/KO and 21 Tie2-CreERT2 littermates was used and 
divided to 3 groups each before isolation. 
GeneChip microarray assay 
Sample preparation for microarray hybridization was carried out as described in the Ambion WT 
Expression Kit Protocol (Life Technologies) and the Affymetrix WT Terminal Labeling and 
Hybridization User Manual (Affymetrix, Inc.). 
Sample processing was performed at an Affymetrix Service Provider and Core Facility, 
“KFB - Center of Excellence for Fluorescent Bioanalytics” (Regensburg, Germany; www.kfb-
regensburg.de). 
Microarray data analysis 
Summarized probe set signals were calculated by using the RMA21 algorithm with the 
Affymetrix GeneChip Expression Console Software. Probe sets with a fold change above 2.0 
fold and a Student’s t test P value lower than 0.05 were considered as significantly regulated 
with n=3 independent experiments. 
FACS
Co-expression of anti-mouse CD11b-APC and CD45-efluor™450 are shown in density plots. 
CD11b+CD45hi cells infiltrate monocytes/macrophages while CD11b+CD45low are the intrinsic 
microglial population.  
Statistical analysis 
All data are presented as scatter dot plots with mean ± standard deviation. Detailed description of 
statistical analysis is provided in the figure legends and in the Online Data Supplements.  
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Results
Conditional ablation of endothelial Stat3  
An endothelial-specific conditional knockout mouse for Stat3 was generated by crossbreeding 
endothelial specific CreERT2 mice (Tie2-CreERT2 mice) with Stat3floxed/KO mice which have the 
exon 22 of Stat3 flanked by LoxP sites. A phosphorylation of the tyrosine residue at position 705 
in the protein domain encoded by the exon 22 is indispensable for activation of Stat3. We used 
the Tie2-CreERT2 mouse generated by Forde et al. (MGI:2450312)17, which showed highly 
specific endothelial expression with negligible expression in hematopoietic cells. To test efficacy 
and specificity of endothelial-Tie2-CreERT2;Stat3floxed/KO after tamoxifen administration we 
performed immunofluorescence co-staining of pStat3(Y705) and caveolin-1. Phosphorylation of 
Stat3 was induced by ischemia. We observed a significant decrease of phosphorylated 
Stat3+/caveolin-1+ endothelial cells of Tie2-CreERT2;Stat3floxed/KO mice compared to their Tie2-
CreERT2 littermates (Figure 1A and B). As expected, we observed no reduction of 
phosphorylated Stat3 in caveolin-1 negative or non-endothelial cells in endothelial-Tie2-
CreERT2;Stat3floxed/KO mice (Figure 1A and C). However, we did observe pStat3+/caveolin-1+ 
cells in endothelial Tie2-CreERT2;Stat3floxed/KO mice with tamoxifen treatment and ischemia. In 
endothelial cells the loss of pStat3(Y705) was still evident at 28 days.  
Increased gene expression and Stat3 phosphorylation 28 days after ischemia 
We determined the expression of Stat3 mRNA after a 30 minute occlusion of the left middle 
cerebral artery (MCAo) and differing reperfusion times up to 28 days after ischemia. In the 
ischemic hemisphere there was a strong increase in Stat3 expression. The mRNA level was 
highest 2 days after reperfusion (4-fold induction) and then declined again at 3 days after 
reperfusion, but levels were still elevated at 28 days (Figure 1D). No induction took place at any 
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time in the non-ischemic hemisphere. The amount of activated Stat3 in endothelial cells was 
determined by immunofluorescence co-stainings for pStat3 and caveolin-1 at 2 days and 28 days 
after cerebral ischemia. In endothelial cells of the peri-infarct area, Stat3 was still being 
phosphorylated at 28 days. Furthermore, at this time point significantly more endothelial cells 
were immunoreactive for pStat3 than had been the case 2 days after ischemia (Figure 1E). 
Conditional ablation of endothelial Stat3 causes worse long-term stroke outcome 
A control group of Endothelial-Tie2-CreERT2;Stat3floxed/KO and Tie2-CreERT2 littermates received 
tamoxifen for five consecutive days and was subjected 2 days later to 30 min MCAo 
(Figure 2A). In MRI imaging 2 days after ischemia no difference was detected between the 
genotypes (Figure 2B and C). A subset of both genotypes (n=12 Tie2-CreERT2 littermates and 
n=9 Tie2-CreERT2;Stat3floxed/KO mice) was killed for histological evaluation of lesion size at 
2 days after ischemia. NeuN-immunohistochemistry and quantification of the lesion size 
consistently failed to reveal any difference in the degree of neuronal loss between endothelial-
Tie2-CreERT2;Stat3floxed/KO and Tie2-CreERT2 littermates (Figure 2D and E). However, at 28 days 
after ischemia we observed that genomic ablation of Stat3 had led to lesion sizes which were 
larger than those in Tie2-CreERT2 littermates (Figure 3A and B). At 14 days after 30 min MCAo 
functional outcome as tested by behavioral analysis was worse: In the Rotarod test the ‘time-to-
drop’ was significantly lower (Figure 3C) and the extended neuroscore in endothelial-Tie2-
CreERT2;Stat3floxed/KO mice was lower (Figure 3D). Taken together, ablation of endothelial Stat3 
had no effect on short-term post stroke outcome. In fact, at 14 days post stroke the functional 
outcome was worse and at 28 days after stroke lesion volume was greater. 
Endothelial Stat3 promotes angiogenesis after cerebral ischemia
Next, we analyzed angiogenesis after cerebral ischemia and endothelial Stat3 ablation. Vessel 
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density was determined by measuring the caveolin-1 positive area (see methods for details). We 
observed at 28 days after reperfusion that endothelial ablation of Stat3 had reduced vessel 
density (Figure 4A and C). The number of caveolin-1 / BrdU double-positive cells was 
significantly reduced by 60% (p < 0.005) (Figure 4B and D) indicating a reduced proliferation 
of endothelial cells. Vessel density in peri-infarct striatal regions was reduced as visualized after 
3D rendering of confocal Z-stacks (Figure 4E and F, Supplemental movie). Il6 induces the 
expression of Vegf by activating the Stat3 signaling pathway. At 2 days and 28 days after MCAo 
we measured the serum levels of Il6 and Vegf using ELISA. There was no difference between 
the two genotypes, either at 2 days or 28 days, either for Il6 or Vegf (Supplemental Figure 1A 
and B, Supplemental Material). 
Endothelial Stat3 ablation is followed by increased percentage of CD11b+/CD45low cells and 
of CD11b+/CD45high cells 
With FACS analysis at 4 days after MCAo we determined the percentage of CD11b+/CD45low 
and CD11b+/CD45high cells in the total cell population. It is generally assumed that 
CD11b+/CD45low are microglial cells and that CD11b+/CD45high cells represent invading 
myeloide cells. We found an increase of CD11b+/CD45low cells in the ischemic hemisphere 
compared to the contralateral hemisphere, and this increase was significantly higher after 
endothelial Stat3 ablation (Figure 4G and H). In Tie2-CreERT2 littermates we found a slight 
trend towards increased invasion of myeloide cells in the ischemic hemisphere compared to the 
contralateral side, whereas a significant increase of invading myeloide cells was evident in 
endothelial-Tie2-CreERT2;Stat3floxed/KO. However, the number of myeloide cells in the ischemic 
hemisphere did not differ significantly between endothelial-Tie2-CreERT2;Stat3floxed/KO and Tie2-
CreERT2 littermates.  
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Endothelial Stat3 ablation results in an anti-angiogenic, axon growth-inhibiting and 
extracellular matrix (ECM)-degrading micro-milieu 
We analyzed the transcriptional profile of CD31-enriched cells at 4 days after cerebral ischemia 
and endothelial Stat3 ablation. Our isolation and enrichment method maintains the interaction 
between endothelial cells and adjacent cells. We determined the cellular composition of the 
isolated cells by immunostaining cytospins after CD31-MACS and found endothelial cells to be 
the dominant fraction (Figure 5A). We found marker genes for endothelial cells, neurons, 
astrocytes and oligodendrocytes to be present in the isolated RNA (Figure 5B). In summary, the 
isolated cell population reflects the cellular composition of the neurovascular niche. 
The expression of 255 genes differed significantly – by more than 2-fold – between the 
genotypes (Supplemental Table 1). Gene arrays were performed from three independent 
experiments with 7 animals per experiment and genotype (in total 21 Tie2-CreERT2;Stat3floxed/KO 
and  21 Tie2-CreERT2 littermates). Overall, we found a complex network response with an 
increase of anti-angiogenic factors and a decrease of angiogenic factors after endothelial Stat3 
ablation (Figure 5C and Table 1). Moreover, we observed an increase of factors that inhibit 
axonal growth and a decrease of factors that promote axonal growth (Figure 5D and Table 2).  
We also identified a decreased expression of several components of the ECM and an induction of 
ECM degrading enzymes. Interestingly, Adamts9, a potent anti-angiogenic and ECM-degrading 
enzyme, is strongly induced after endothelial Stat3 ablation. In the rat it is reported to be 
expressed exclusively in neurons and astrocytes directly after cerebral ischemia.22 In immune 
staining we found Adamts9 to be expressed mainly in endothelial cells of the peri-ischemic area 
at 4 days after ischemia (Figure 6A). Additionally, we found a slight but significant increase of 
ROS-producing genes like iNOS and NOX4 and induced expression of CD14 (Table 1, 
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supplements). These changes point to an increased inflammatory activation after endothelial 
Stat3 ablation. 
In summary, endothelial Stat3 ablation leads to a shift of the transcriptional profile within 
the neurovascular niche towards an anti-angiogenic and axon growth inhibiting micro-milieu. 
Moreover, we found a shift towards an ECM degrading micro-milieu. 
Endothelial Stat3 ablation changes the glycosylation pattern of the ECM after cerebral 
ischemia
The composition of the ECM changes after cerebral ischemia.23 Prominently, the expression of 
proteogylcans is increased. This type of ECM composition hinders growing axons from entering 
the lesion volume and thereby impairs axonal plasticity and functional recovery. The axon 
growth inhibiting properties of the proteoglycans are conditioned by the glycosylation pattern of 
the glycosaminoglycan side chains.23 Isolectin-B4 is a lectin derived from Griffonia simplicifolia 
that binds terminal Į-D-galactosyl residues which are present mainly on the surface of 
endothelial and monocytic cells. It has been shown that isolectin-B4 binds the proteoglycan 
versican.24 We stained the brains with isolectin-B4 at 28 days after cerebral ischemia to identify 
functional changes in ECM in the genotypes. With isolectin-B4 we found an increased staining 
of the ECM in the ischemic area (Figure 6 B). Moreover, the volume of the isolectin-B4 positive 
ECM-area increased after endothelial Stat3 ablation (Figure 6B and C). 
Discussion
The major finding of this study is that activation of endothelial Stat3 is crucial for long-term 
outcome after stroke. We generated an endothelial-specific and inducible knockout mouse model 
by crossbreeding mice (Tie2-CreERT2;Stat3floxed/KO) to analyze the function of endothelial Stat3 in 
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stroke. Endothelial Stat3 ablation caused increased lesion size in the long-term after stroke, but 
not in the short-term. Angiogenesis was reduced while the percentage of microglia increased, 
indicating microglia proliferation. The expression profile within the neurovascular niche was 
changed to an anti-angiogenic, axon growth inhibiting micro-milieu with ECM degradation. 
Most prominently, expression of the anti-angiogenic and proteoglycan-cleaving Adamts9 was 
induced after endothelial Stat3 ablation and cerebral ischemia. We found Adamts9 to be 
expressed mainly in endothelial cells in the peri-ischemic area. Moreover, after endothelial Stat3 
ablation we found altered glycosylation patterns of the ECM. In the end, functional outcome was 
worse after endothelial Stat3 ablation and cerebral ischemia. 
Short-term analysis of lesion volumes 2 days after reperfusion revealed no differences 
between the genotypes, either in MRI or in histology, after 30 min MCAo (Figure 2A-D). This 
confirms previous data on the kinetics of Stat3 phosphorylation: Stat3 is highly induced and 
activated in neurons in the ischemic core and peri-infarct region within 8 hours after stroke.8 
Stat3 exerts its anti-apoptotic effects in neurons.11, 25, 26 Stat3 phosphorylation in contrast does 
not start in endothelial cells before 48 hours after ischemia.8 An endothelial-specific knockout of 
Stat3 should therefore not impact on the acute outcome after stroke. Our results thus fit nicely 
together with the known kinetics of endothelial Stat3. We compared genotype lesion sizes at 
28 days after ischemia and detected yet upregulated and phosphorylated Stat3 in endothelial cells 
(Figure 1D and E). Endothelial Stat3 ablation increased the lesion volume at this later time 
point (Figure 3A and B). 
At 28 days after ischemia vessel density (Figure 4A and C) and endothelial cell 
proliferation (Figure 4B and D) were reduced after endothelial Stat3 ablation. After cerebral 
ischemia Stat3 is activated by several inflammatory factors such as Il6, Lif or Cntf.27-29 
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Activation of Stat3 by Il6 is followed by increased angiogenesis which is in part mediated by 
transcriptional induction of Vegf.30 This led us to seek differences in Il6 and Vegf serum levels 
after endothelial knockout of Stat3. Contrary to our expectations, however, endothelial ablation 
of Stat3 had no impact on systemic Il6 or Vegf levels (Figure 1A and B, supplements). 
Endothelial Stat3 is apparently not involved in elevated Il6 serum levels after cerebral ischemia, 
and the induction of angiogenesis after stroke by Stat3 activation is independent of Vegf.  
We established a method to isolate endothelial cells and adjacent cells of the 
neurovascular niche after endothelial Stat3 ablation and cerebral ischemia and we analyzed the 
transcriptional profile of this cell population by gene array analysis. Capillary endothelial cells 
are embedded in a firm basal membrane consisting mainly of collagens. The triple helix structure 
of collagens can be destroyed by collagenase digestion but is resistant to cleavage by trypsin, 
pepsin or papain.31 Therefore we digested the brain matrix with papain to maintain the 
interaction between the basal membrane of the vasculature and the adherent cells of the 
neurovascular niche. Endothelial cells and all adherent cells were isolated by CD31-MACS. We 
chose a time point 4 days after ischemia, when angiogenesis and axonal growth are still going on 
but mechanisms of the acute phase after ischemia have already ceased. 
In the CD31-enriched population 4 days after cerebral ischemia, we identified 255 genes 
which showed differing expression levels between genotypes (Supplemental Table 1). Overall 
endothelial Stat3 ablation led to an anti-angiogenic and axon growth inhibiting micro-milieu 
(Figure 5A and B). Interestingly, endothelial Tie2-CreERT2;Stat3floxed/KO mice showed higher 
expression of apelin, apelin receptor and placental growth factor – all potent angiogenic factors – 
than did their Tie2-CreERT2 littermates. This might indicate a compensatory activation of 
alternative angiogenic pathways which after activation, however, did not change angiogenesis. It 
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is known that after ischemia, the outgrowing vessels support neuroblast migration in a scaffold-
like manner, directing migration to the damaged areas.2 The reduction of angiogenesis after 
endothelial Stat3 ablation precludes this process and might thus contribute to impaired 
neuroplasticity. 
Most prominent was an increased expression of Adamts9 with strong anti-angiogenic 
activity.32 It is reported that Adamts9 in the rat is mainly expressed in neurons 24 hours after 
cerebral ischemia.22 We found its expression mainly in endothelial cells in the peri-ischemic 
tissue 4 days after ischemia. Adamts proteases are classified in three sub-families based on their 
preference for cleaving specific ECM components.33 Adamts9 belongs to the proteoglycanases 
and degrades chondroitin sulfate proteoglycans (CSPGs). CSPGs are major components of the 
ECM and are characterized by a core protein with at least one covalently bound 
glycosaminoglycan side chain and a variable number of N- and O-linked oligosaccharides.  
After cerebral ischemia the composition of the ECM is changed to a more ‘juvenile 
matrix type’.34 Therefore the ECM first has to be degraded. In proteoglycans this is performed 
predominantly by Adamts proteases. Finally the expression of all proteoglycans is much higher 
after ischemia, and they contribute to a large extent to the development of the ECM component 
in the lesion volume. The chronic lesion volume on the one hand improves the physical stability 
of the ischemic area, on the other hand it strongly impairs neuroplasticity.23 Thus digestion of 
proteoglycans by Adamts proteases is thought to have beneficial effects.33 Endothelial Stat3 
ablation led to an intense upregulation of Adamts9 which quite specifically cleaves the long 
variants of the proteoglycans – aggrecan and versican – but not the short proteoglycan brevican. 
However, the expression of the short proteoglycans neurocan and brevican was reduced, as was 
the expression of tenascinR. Also reduced was the expression of phosphacan and its cellular 
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binding partners Ncam, Nrcam and contactin2.  
In general, the expression pattern of the matrix within the neurovascular niche was shifted 
towards the ‘juvenile matrix type’ with a looser mesh-size and thus axon growth-promoting 
ECM-environment, with less inter-cellular ECM binding after endothelial Stat3 ablation. 
Nonetheless, the expression of other axon growth inhibiting genes and the suppression of growth 
promoting genes seemed to outweigh this effect after endothelial Stat3 ablation. Adamts9 
expression was not able to reduce chronic lesion size or improve functional outcome. 
Furthermore, in isolectin-B4 staining we found an increase of Į-D-galactosyl residues in the 
chronically damaged tissue. The axon growth inhibiting activity of proteoglycans is partly 
mediated by their glycosylation patterns. Endothelial Stat3 might  be highly relevant for 
regulation of the glycosylation pattern of the ECM in the chronic lesion and might thereby 
influence axon growth and neuroplasticity. 
Beyond that, we found a slightly increased invasion of monocytes 4 days after cerebral 
ischemia and endothelial Stat3 ablation. Proliferation of microglia was increased. The expression 
of ROS-building genes such as iNOS and NOX4 as well as CD14 was higher, which might 
contribute to delayed neuronal cell death and increased lesion size in the long-term after 
ischemia.  
As a consequence, treatment strategies that focus on Stat3 signalling of endothelial cells 
offer the following three advantages: 1) accessibility for intravenous treatment, 2) treatment 
options in the acute phase of stroke beyond the narrow time window for thrombolysis, 3) 
pleiotropic neuroregenerative action with widespread consequences for brain plasticity through 
changes in the micro-environment. Although this study provides substantial insight into the 
consequences of endothelial Stat3 signalling on long-term outcome after cerebral ischemia, 
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further studies need to address the beneficial effects of endothelial-specific Stat3 signalling as a 
treatment option. We suggest using drugs that do not pass the blood brain barrier in order to 
achieve an endothelial-specific stimulation of Stat3 and avoid activation of microglial Stat3, 
which might have detrimental consequences. 
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Table 1. Gene array results of angiogenesis-related genes in the neurovascular niche 
Gene
symbol Gene description 
Fold change
Tie2-
CreERT2;
Stat3floxed/KO
vs
Tie2-CreERT2
p-value
(t-test) Gene accession 
Adamts9 a disintegrin-like and 
metallopeptidase (reprolysin type) 
with thrombospondin type 1 
motif, 9  
5.02 0.00 NM_175314  
Sfrp4 secreted frizzled-related protein 4 2.85 0.01 ENSMUST00000169327 
Timp1 tissue inhibitor of 
metalloproteinase 1  
2.51 0.00 
NM_001044384  
Cd36 CD36 antigen  2.47 0.00 NM_001159557  
Thbs1 thrombospondin 1  2.02 0.00 NM_011580  A
nt
i-a
ng
io
ge
ni
c 
Agt angiotensinogen (serpin peptidase 
inhibitor, clade A, member 8)  
-3.08 0.01 NM_007428  
Tnr tenascin R  -4.80 0.03 NM_022312  
Edil3 EGF-like repeats and discoidin  
I-like domains 3  
-4.30 0.01 NM_001037987  
Nrxn1 neurexin I  -3.87 0.03 NM_020252  
Pcdh10 protocadherin 10  -3.69 0.04 NM_001098171  
Cdh19 cadherin 19, type 2  -3.52 0.04 NM_001081386  
Nrcam neuron-glia-CAM-related cell 
adhesion molecule  
-3.10 0.01 NM_176930  
Nlgn1 neuroligin 1  -2.96 0.05 NM_138666  
Olfm3  olfactomedin 3  -2.39 0.04 NM_153157  
Ptk2b PTK2 protein tyrosine kinase 2 
beta  
-2.18 0.04 NM_001162365  
Prkca protein kinase C, alpha  -2.09 0.05 NM_011101  
Cdh12 cadherin 12  -2.01 0.01 NM_001008420  
Apln apelin  2.19 0.00 NM_013912  
Bmp2 bone morphogenetic protein 2  2.63 0.03 NM_007553  
Hmox1 heme oxygenase (decycling) 1  3.12 0.00 NM_010442  
Pgf placental growth factor  4.11 0.00 NM_008827  
Aplnr apelin receptor  7.46 0.00 NM_011784  
Tnr tenascin R  -4.80 0.03 NM_022312  
Edil3 EGF-like repeats and discoidin  
I-like domains 3  
-4.30 0.01 NM_001037987  
Nrxn1 neurexin I  -3.87 0.03 NM_020252  
an
gi
og
en
ic
Pcdh10 protocadherin 10  -3.69 0.04 NM_001098171  
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Table 2. Gene array results of axonogenesis-related genes in the neurovascular niche 
Gene
symbol Gene description 
Fold change
Tie2-
CreERT2;
Stat3floxed/KO
vs
Tie2-CreERT2
p-value
(t-test) Gene accession 
Kit kit oncogene  3.91 0.00 NM_001122733  
Lamb1 laminin B1  2.23 0.02 NM_008482  
Olfm1  olfactomedin 1  -2.00 0.02 NM_019498  
Camk4 calcium/calmodulin-dependent 
protein kinase IV  
-2.04 0.04 NM_009793  
Slitrk4  SLIT and NTRK-like family, 
member 4  
-2.09 0.01 NM_178740  
Prkca protein kinase C, alpha  -2.09 0.05 NM_011101  
Ntrk3 neurotrophic tyrosine kinase, 
receptor, type 3  
-2.21 0.05 ENSMUST00000039431 
Mtap2 microtubule-associated protein 2 -2.21 0.03 NM_001039934  
Kif5c  kinesin family member 5C  -2.22 0.05 NM_008449  
Unc5a unc-5 homolog A (C. elegans)  -2.31 0.04 ENSMUST00000026994 
Slitrk1  SLIT and NTRK-like family, 
member 1  
-2.32 0.05 NM_199065  
Chn1 chimerin (chimaerin) 1  -2.44 0.03 NM_001113246  
Pak3 p21 protein (Cdc42/Rac)-
activated kinase 3  
-2.46 0.03 ENSMUST00000112863 
Ntm neurotrimin  -2.46 0.04 NM_172290  
Robo2 roundabout homolog 2 
(Drosophila)  
-2.53 0.01 NM_175549  
Celsr2 cadherin, EGF LAG seven-pass 
G-type receptor 2 (flamingo 
homolog, Drosophila)  
-2.65 0.03 NM_017392  
Cyfip2 cytoplasmic FMR1 interacting 
protein 2  
-2.79 0.02 NM_133769  
Nlgn1 neuroligin 1  -2.96 0.05 NM_138666  
Chl1 cell adhesion molecule with 
homology to L1CAM  
-2.99 0.02 NM_007697  
Tbr1 T-box brain gene 1  -3.06 0.02 NM_009322  
Nlgn3 neuroligin 3  -3.08 0.02 NM_172932  
ax
on
 g
ro
w
th
 p
ro
m
ot
in
g 
Nrcam neuron-glia-CAM-related cell 
adhesion molecule  
-3.10 0.01 NM_176930  
 Mdga2  MAM domain containing 
glycosylphosphatidylinositol 
anchor 2  
-2.91 0.03 NM_001193266  
Dclk1 doublecortin-like kinase 1  -3.32 0.05 ENSMUST00000167204 
axa
nnon
 g
roro
w
t
w
t
w
thhh
rprpr
omomom
oto
in
g
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Ncam1 neural cell adhesion molecule 1 -3.53 0.02 NM_001081445  
Reln reelin  -3.65 0.00 NM_011261  
Pcdh10 protocadherin 10  -3.69 0.04 NM_001098171  
Dock3 dedicator of cyto-kinesis 3  -3.78 0.03 NM_153413  
Ptprz1  protein tyrosine phosphatase, 
receptor type Z, polypeptide 1  
-3.91 0.05 NM_001081306  
Slitrk3  SLIT and NTRK-like family, 
member 3  
-3.95 0.03 NM_198864  
Lrrc4c leucine rich repeat containing 
4C  
-4.04 0.02 NM_178725  
Bai3 brain-specific angiogenesis 
inhibitor 3  
-4.86 0.04 ENSMUST00000151309 
Xylt1 xylosyltransferase 1  -2.15 0.05 NM_175645  
A
xo
n 
gr
ow
th
 
in
hi
bi
tin
g Pdlim1 PDZ and LIM domain 1 (elfin)  4.07 0.01 NM_016861  
A
x i
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Figure Legends: 
Figure 1. Endothelial-specific ablation of Stat3. Endothelial Stat3 ablation was induced in Tie2-
CreERT2;Stat3floxed/KO mice by tamoxifen administration for five consecutive days. Tie2-CreERT2 
littermates with tamoxifen injections served as controls. Mice received a 30 min MCAo 2 days 
after the last tamoxifen injection. Endothelial Stat3 ablation was confirmed by staining of pStat3 
and caveolin-1 4 days or 30 days after the last tamoxifen administration and shown as a ratio to 
the caveolin positive area (B). Images were taken in 200x magnification in the peri-ischemic 
subcortical region (A). pStat3 positive and caveolin-1 negative cells (C) were counted per view. 
Scatter dot blots are mean cell counts of triplicate fields per mouse and are presented as mean ± 
s.d.. Regression analysis with robust variance estimates yielded significant differences between 
day 2 and day 28 (p<0.001); values for WT mice were significantly higher (p<0.001), and 
differences between Tie2-CreERT2 and Tie2-CreERT2;Stat3floxed/KO were significantly higher at day 
28 than at day 2 (interaction: p=0.003). C: Number of pStat3 positive and caveolin-1 negative 
cells. D: Expression of Stat3 mRNA of ischemic and contralateral hemispheres of wildtype mice 
determined by real-Time RT-PCR. Data are presented as mean ± s.d. of 3 – 4 mice or 2 mice 
(native brains) per time point and group. Stat3 mRNA (log-transformed) after MCAo was tested 
over time in wildtype mice ipsi/contra with a linear mixed model including an interaction term 
for time*ipsi/contra to account for clustering of data in mice (random intercept model). E: 
Endothelial Stat3 activation was determined by immunofluorescence co-staining of pStat3 and 
caveolin-1. The number of pStat3 / caveolin-1 double positive cells was counted and expressed 
as a ratio of the caveolin-1 positive area and within the peri-infarct region at 2 days and 28 days 
after ischemia. Unequal variance t-test for independent samples was used. *p < 0.001 for B, D 
and E.  
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Figure 2. Endothelial Stat3 ablation has no effect on ischemic lesion volume 2 days after 
cerebral ischemia. Tie2-CreERT2 littermates (n=23) and Tie2-CreERT2;Stat3floxed/KO (n=16) mice 
received tamoxifen on five consecutive days followed after a 2 day interval by a 30 min MCAo. 
A: Timeline of experimental setup. B-C: Ischemic lesion size was determined by MRI after 
2 days. D-E: A subset of each genotype (n=12 for Tie2-CreERT2 littermates, n=9 for Tie2-
CreERT2;Stat3floxed/KO) was killed at this time point for lesion volume analysis by NeuN-DAB 
staining. There was no difference in lesion volume between the two groups two days after 
cerebral ischemia. Data are presented as scatter dot plots with mean ± s.d. and analyzed by two-
tailed Student’s t-test (p = 0.25 and p = 0.19, respectively). *p < 0.05 and **p < 0.01 in B-D.  
Figure 3. Endothelial-specific ablation of Stat3 increases lesion volume 28 days after cerebral 
ischemia and impairs functional outcome 14 days after cerebral ischemia. Tie2-CreERT2 
littermates (n=11) and Tie2-CreERT2;Stat3floxed/KO (n=7) were subjected to 30 min MCAo after 5 
days of daily tamoxifen administration followed by an interval of 2 days, and were killed at 28 
days after the onset of cerebral ischemia. Lesion volume was determined by NeuN-DAB staining 
(A-B). Data are presented as scatter dot plots with mean ± s.d. and analyzed by two-tailed 
Student’s t-test with p = 0.01 versus littermates. C: Rotarod. Data are presented as bar graphs 
with mean ± s.d and analyzed by two-tailed Student’s t-test with p = 0.04 versus littermates 
(Tie2-CreERT2 littermates n=12, Tie2-CreERT2;Stat3floxed/KO n=12). D: extended neuroscore. Data 
are analyzed by Mann-Whitney U test with p = 0.03 (Tie2-CreERT2 littermates n=12, Tie2-
CreERT2;Stat3floxed/KO n=12). 
Figure 4. Post-ischemic angiogenesis is reduced after endothelial-specific ablation of Stat3 and 
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microglia proliferation is increased. Tie2-CreERT2 littermates (n=11) and Tie2-
CreERT2;Stat3floxed/KO (n=7) were subjected to 30 min MCAo after 5 days of daily tamoxifen 
administration followed by a free interval of 2 days and were killed 28 days after cerebral 
ischemia and stained for caveolin-1. A: Multiple image alignment of caveolin-1 stained brain. C: 
The caveolin-1 positive area above a preset threshold was determined using semiautomatic 
software algorithms and presented as a ratio of ipsilateral and contralateral hemispheres. Data are 
presented as scatter dot blots with mean ± s.d. and analyzed using two-tailed Student’s t-test with 
p = 0.01. B: Ischemic hemispheres were stained for caveolin-1 and anti-BrdU. D: Vessel 
associated BrdU double positive cells (caveolin-1+/BrdU+) were counted per mm2 and presented 
as scatter dot plots with mean ± s.d. and analyzed using two-tailed Student’s t-test with 
p = 0.003. E-F: 3D projections of peri-infarct vascular networks. G-H: FACS analysis of the 
numbers of CD11b+/CD45low (microglia) and CD11b+/CD45high (monocytes) 4 days after 
ischemia. The percentage of microglia is increased 4 days after ischemia in the ischemic 
hemisphere, and the increase is significantly higher after endothelial Stat3 ablation. FACS data 
were analyzed with a linear mixed model using FACS as dependent variable (log-transformed) 
and genotype, CD11b+/CD45low/CD11b+/CD45high and ipsilateral/contralateral as independent 
variables. In the model we also included interaction terms for genotype*ipsi/contra and 
CD11b+/CD45low/CD11b+/CD45high*genotype. All p-values (*< 0.05; **< 0.01, and ***< 0.001) 
reported are derived from regression based post hoc tests using Bonferroni-adjustment for 
multiple testing.  
Figure 5. Endothelial Stat3 ablation leads to an anti-angiogenic and axon-growth inhibiting 
micro-milieu within the neurovascular niche. Tie2-CreERT2 littermates and Tie2-
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CreERT2;Stat3floxed/KO were subjected to 30 min MCAo after 5 days of daily tamoxifen 
administration followed by a free interval of 2 days, and were killed 4 days after cerebral 
ischemia. CD31-enriched cells were isolated and a gene array performed (n=3; total number of 
animals per genotype=21 with 7 animals pooled for enrichment). A: Staining of cytospins of 
CD31-MACS sorted cells with caveolin-1 and DAPI. B: Expression levels of marker genes 
specific for endothelial cells, neurons, astrocytes or oligodendrocytes.  Fold expression of 
angiogenesis-related (C) and axon growth-related (D) genes compared between Tie2-
CreERT2;Stat3floxed/KO and Tie2-CreERT2 littermates. For testing expression levels of angiogenic or 
axon-modulating genes between WT and KO we used one sample t-test to test fold_mRNA 
against the hypotheses that these values are 0 on average. For anti-angiogenic genes the fold 
change was on average 2.0 (p=0.133); for angiogenic genes it was -1.6 (p=0.054), for axon 
growth promoting genes it was -2.5 (p<0.001) and for axon growth inhibiting genes it was 0.6 
(p=0.884).  
 
Figure 6. Endothelial Stat3 ablation increases Adamts9 and extracellular matrix glycosylation.
Tie2-CreERT2 littermates (n=11) and Tie2-CreERT2;Stat3floxed/KO mice (n=7) were subjected to 
30 minute MCAo after 5 days of daily tamoxifen administration followed by a free interval of 
2 days and were killed 4 days (A) or 28 days (B, C) after ischemia. A: Staining of Adamts9 and 
caveolin-1. 4 days after ischemia Adamts9 is mainly expressed in endothelial cells. (B-C): 
Staining of cryosections 28 days after ischemia with isolectin-B4. Isolectin-B4 stains 
components of the ECM in the ischemic hemisphere. The isolectin-B4 positive volume is 
increased after endothelial Stat3 ablation. *p < 0.05.  
Figure 1
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SUPPLEMENTAL MATERIAL 
Supplemental Methods 
Animals and treatments 
All animal experiments were approved by the local governmental authorities (Landesamt für 
Gesundheit und Soziales, G0354/11). Mice had access to food and water ad libitum and 
were kept under a 12 hours light and dark cycle. Stat3floxed/KO mice1 were crossbred with Tie2-
CreERT2 mice.2 Both transgenic mouse lines were backcrossed onto a C57Bl/6_N background 
and littermates were used for the experiments. Mice were genotyped by standard 
polymerase chain reaction protocols. Endothelial specific knock out of Stat3 was induced by 
a 5 day i.p. application of Tamoxifen (1 mg/d) which results in an excision of exon 22 that 
codes for the domain including tyrosine 705 (Y705) which is phosphorylated for activation of 
Stat3. Tie2-CreERT2 littermates served as control group. The concealment to the genotypes 
was blinded throughout the entire experiment and histological analysis. Scientists were 
blinded to the allocation of the mice to the groups. Litters were caged in mixed groups after 
heterozygous breeding and undergone surgery after randomization. Animals for experiments 
were gender and age matched. Tie2-CreERT2 littermates and Tie2-CreERT2;Stat3floxed/KO mice 
were 4.8 ± 1.8 and 4.6 ± 1.6 month old. The sex ratio between Tie2-CreERT2 littermates and 
Tie2-CreERT2;Stat3floxed/KO mice did not differ as analyzed using Fisher’s Exact test. 
Endothelial specific knock out of Stat3 was confirmed by immunofluorescence staining of 
phosphorylated Stat3 (Y705). Mice received BrdU (50 µg/g body weight) i.p. from day 2-7 
after MCAo at a concentration of 10 mg/ml. 3 animals in total were excluded from the study 
due to the lack of a lesion while two of them being Tie2-CreERT2 littermates and 1 Tie2-
CreERT2;Stat3floxed/KO. 
 
Model of middle cerebral artery occlusion (MCAo) 
Filamentous middle cerebral artery occlusion of the left side was performed for 30 minutes 
with indicated reperfusion time points according to the published standard operating 
procedure in our laboratory.3 In brief, mice were anesthetized with 1.0% isofluorane in a 
mixture of 70% vol/vol N2O and 30% vol/vol O2 using a vaporizer and face mask. Brain 
ischemia was induced with an 8.0 nylon monofilament coated with a silicone resin /hardener 
mixture (Xantopren M Mucosa and Activator NF Optosil Xantopren, Haereus Kulzer, 
Germany) as described. The filament was introduced into the left internal carotid artery up to 
the anterior cerebral artery. Thereby, the middle cerebral artery and anterior choroidal 
arteries were occluded. Filaments were withdrawn after 30 min to allow reperfusion. 
 
RNA-isolation 
Mice were deeply anesthetized, cardially perfused with NaCl-solution, decapitated and the 
brain removed after 2, 3, 7, and 28 days of reperfusion. The brains were cut in 1 mm coronal 
slices using a brain matrix. In the slices ischemic and contralateral hemispheres were 
separated and snap frozen and pestled in liquid nitrogen, homogenized using a Dounce 
homogenizer and RNA was extracted using Trizol (Invitrogen). RNA was stored at -80 °C 
prior to transcription. 
 
Real-time RT-PCR 
1 µg of RNA was transcribed with MLV-reverse transcriptase (Promega) using random 
primers (Roche) and oligo-dT primers (Eurofins-MWG). Real-time PCR was performed with 
intron spanning primers for Ywhaz and Sdha as internal controls and primers for Stat3 using 
Sybr green (Qiagen). Comparable primer efficiency was confirmed. For all runs melting 
curves were analyzed. No template and untranscribed RNA served as negative controls. 
Fold-amount of mRNA compared to mean of internal controls was calculated using the 
equation: 2-(Ct(gene of interest)-Ct(internal control)) 
 Histology and immunofluorescence 
Mice were deeply anesthetized, cardially perfused with NaCl-solution, decapitated, and 
brains snap frozen in -40 °C isopentane for cryostat sectioning at 2 and 28 days after MCAo. 
20 µm cryosections were fixed with Aceton/Methanol for 10 min at -20 °C and washed 
3 times for 5 min with PBS. Sections that were stained for caveolin-1 (B&D) or 
pStat3 (Tyr705) (Cell signaling) were blocked in PBS with 10 % normal goat serum and 
0.1 % Triton for 1 h and incubated with caveolin-1 (1:100, BD), Adamts9 (1:50; Santa Cruz) 
or pStat3 (1:50, Cell signaling) antibodies over night, washed 2 times with PBS, incubated 
with goat anti-mouse antibody (1:400, conjugated with Alexa 488) or goat anti-rabbit antibody 
(1:400, conjugated with Alexa 594) for 2 h, washed 2 times for 5 min with PBS, incubated 
3 min with DAPI, washed 2 times with water and mounted with immunomount (GeneTex). 
Sections that were stained for BrdU were incubated with 2 N HCl for 30 min at 37 °C followed 
by an incubation in 0.1 M borate buffer for 10 min at room temperature, washed 6 times for 
10 min with TBS, blocked in TBS with 10 % normal goat serum and 0.1 % Triton for 30 min, 
incubated with primary antibody against BrdU (1:100, AbD Serotec) in TBS with 1 % normal 
goat serum and 0.1 % Triton over night, washed 2 times for 5 min with TBS and 1 time for 
15 min with TBS with 1 % normal goat serum and 0.1 % Triton, incubated with secondary 
antibody (1:400) for 2 h washed 2 times for 5 min with PBS, incubated 3 min with DAPI, 
washed 2 times with water and mounted with immunomount (GeneTex). Sections stained for 
NeuN were incubated with 0.3 % H2O2, washed 3 times for 5 min with PBS, blocked in PBS 
with 1 % normal goat serum and 0.1 % Triton for 30 min, incubated wit anti-NeuN-biotin 
antibody (1:100, Chemicon (Millipore)) over night, washed 3 times for 5 min with PBS, 
incubated with VECTASTAIN Elite ABC-kit reagent (Vector labs) for 1 h, washed 3 times for 
5 min with PBS, incubated with Vector DAB substrate (Vector labs) for 10 min, washed 
3 times for 5 min with water, dehydrated with ethanol, incubated with Rotihistol (Carl Roth) 
and mounted with Vitroclud (R. Langenbrinck, Labor- und Medizintechnik).  
For orthogonal projections, brains were perfused with NaCl-solution with subsequent 4% 
PFA perfusion, and brains were vibratome-sliced into frontal 500 µm sections, incubated with 
isolectin-B4 (Griffonia simplicifolia) conjugated to Alexa Fluor 594 (Life Technologies, 
Carlsbad, Germany) without further permeabilization to specifically label the blood vessel 
network. In addition, the slices were optically cleared with a solution consisting of 4 M urea, 
10% glycerol (v/v), 0.1% TritonX-100 (v/v) for 2 days. 
Microscopy 
Widefield fluorescence microscopic images were collected using an Olympus IX81 inverted 
microscope equipped with a MT10 illumination system, a CCD camera (Hamamatsu, 
Ammersee, Germany) and a Scan FM table (Maerzhaeuser, Wetzlar, Germany) for 
automated image acquisition under the control of Xcellence software (Olympus, Hamburg, 
Germany). For whole brain slice images (multiple image alignments) UPlan FLN 4x and for 
all other images LCACHN 20x were used. 
Confocal images of isolectin B4 stained vascular networks were collected with a spinning 
disc system consisting of a Axio Observer Z.1 microscope (Zeiss, Jena, Germany) equipped 
with a Yokogawa CSU-X1 unit using a 20x/0.4 Korr M27 objective and processed with 
ZEN2012 software (Zeiss, Jena, Germany). Orthogonal projections (60 µm) and 
supplementary movie were generated by ImageJ. 
Lesion volume determination and behavioral tests 
Cerebral lesion volume was quantified with ImageJ analysis software (NIH, USA) on 20 µm 
NeuN-DAB-stained cryostat sections and calculated by summing the infarct sizes of each 
section as described previously.3 To assess motor coordination, a Rotarod test was used 
(TSE Sytems). Mice were placed on an accelerating rotating rod (acceleration from 2 rpm to 
40 rpm within 5 min) and a stop-clock was started. When the mice dropped and touched the 
sensing platform below, the stop-clock stopped automatically. Each animal performed three 
trials.  
An extended neuroscore that consisted of several components was performed. The first 
component was a modified Bederson score that provided a quick overall assessment of the 
activity and locomotor capabilities of the mouse with a score of 0 indicating normal 
spontaneous movement, a score of 4 indicating no movement, and circling behaviours or 
forelimb flexion making up the middle range of the score.4 The next three components 
consisted of 3 point score hand tests. The first two require that the mouse be lowered by the 
base of the tail towards the lid of the home cage. A mouse would score 0 (normal postural 
reflex) if both forelimbs were extended, while a score of 2 would be assigned for 
asymmetrical forelimb extension or curved body posture. An animal would score 0 on the 
third component (normal forelimb grasping reflex) if both forelimbs grasped the lid of the 
home cage, versus 1 for asymmetrical grasping, or 2 for no grasping. Finally, the vertical 
screen test was conducted in which the animal was placed on the lid of the home cage and 
the lid was gently tilted to a 90 ° angle. A score of 0 would indicate normal locomotor 
behaviour as the mouse would hang on and climb around, whereas a score of 2 indicates the 
inability to remain on the lid, or jumping off. A composite score was determined for each 
mouse at each timepoint. 
For lesion size determination a total number of 16 endothelial-Tie2-CreERT2;Stat3floxed/KO and 
23 wildtype littermates were used. All underwent MRI at 2 days after ischemia. A subset of 9 
endothelial-Tie2-CreERT2;Stat3floxed/KO and 12 wildtype littermates were killed at 2 days after 
ischemia and a subset of 7 endothelial-Tie2-CreERT2;Stat3floxed/KO and 11 wildtype littermates 
at 28 days for histological lesion size determination. For behavioral tests 12 endothelial-Tie2-
CreERT2;Stat3floxed/KO and 12 wildtype littermates were used. 
 
MRI 
Magnet resonance imaging (MRI) was performed using a 7 Tesla rodent scanner 
(Pharmascan 70 ⁄ 16AS) with a 16 cm horizontal bore magnet and a 9 cm (inner diameter) 
shielded gradient with an H-resonance-frequency of 300 MHz and a maximum gradient 
strength of 300 mT/m. For imaging a 1H-RF quadratur-volume resonator with an inner 
diameter of 20 mm was used. Data acquisition and image processing were carried out with 
the Bruker software Paravision 4.0. During the examinations mice were placed on a heated 
circulating water blanket to ensure constant body temperature of 37 °C. Anaesthesia was 
induced with 2.5% and maintained with 1.0–2.0% isoflurane delivered in an O2/N2O mixture 
(30/70%) via a facemask under constant ventilation monitoring. A RARE-T2-weighted 
sequence was used. Imaging parameters: for T2 TR / TE = 4200 / 36 ms, RARE factor 8, 4 
averages). 20 axial slices with a slice thickness of 0.5 mm, a field of view of 2.75 x 2.75 cm 
and a matrix of 256 x 256 were positioned over the brain excluding olfactory bulb. Data 
evaluation was performed with Analyse 5.0.  
For stroke volumetry the hyperintense areas of ischemic tissue in T2-weighted images were 
assigned with a region of interest tool (ROI). This enables a threshold-based segmentation 
by connecting all pixels within a specified threshold range about the selected seed pixel and 
results in a 3D object map of the whole stroke region. Further the total volume of the whole 
object map was automatically calculated.  
 
Vessel density determination by immunofluorescence 
Vessels were stained with anti-caveolin-1 antibodies and images of the brain section 
containing the ischemic area were taken in 40x magnification and aligned to a multiple image 
alignment (MIA) of the complete brain section. The area stained for caveolin-1 was 
determined using ImageJ software by selecting a constant color threshold for all MIAs. The 
ratio of the area of caveolin-1 on the ischemic hemisphere to the area on the contralateral 
hemisphere was calculated to normalize the values for different brain sizes. In addition 
caveolin-1 and BrdU double positive cells were counted. 
 
ELISA 
ELISA assays for determining Vegf (R&D systems) and Il6 (Invitrogen) levels were 
performed according to manufacturer’s instructions. 
 
Isolation of CD31-enriched cells 
Mice were euthanized 4 days after cerebral ischemia by i.p. injection of 200 μl pentobarbital-
sodium (Narcoren, Pharmazeutischen Handelsgesellschaft) and perfused using a 0.9 % 
NaCl solution. The brain was extracted and stored in ice-cold HBSS (Gibco-Invitrogen). The 
olfactory bulbs and the cerebellum were cut by a scalpel and discarded. The ipsi- and 
contralateral hemispheres were divided and processed separately. Hemispheres from 6-
8 animals were pooled.  
The tissue was dissociated using the Papain Neural Tissue Dissociation Kit (Miltenyi Biotec, 
Bergisch-Gladbach, Germany) according to the manufacturer’s instructions. To remove the 
myelin we followed a protocol published elsewhere.5 In brief, per one hemisphere the brain 
cell suspension was mixed with a total of 25 ml of a 22 % Percoll (Th.Geyer, Renningen, 
Germany) solution and a layer of 5 ml cold PBS (Gibco-Invitrogen) was added on top. 
Centrifugation at 950 g with slow acceleration and without breaks created a gradient that 
separated the cell pellet on the bottom of the tube from the myelin which was carefully 
aspirated. The cell pellet was resuspended in sorting buffer for subsequent magnetic-
activated cell sorting (MACS) or flow cytometry analysis. A total number of 21 endothelial-
Tie2-CreERT2;Stat3floxed/KO and 21 wildtype littermates were used and divided to 3 groups each 
before isolation. 
 
MACS sorting 
The CD31+ samples for the microarray were generated using MACS. Following percoll 
gradient centrifugation, cell pellets were resuspended in PBS, containing 0.5% FCS and 2 
mM EDTA and labeled with anti-CD31 microbeads™ (Miltenyi Biotec, 130-097-418). The 
MACS isolation was carried out according to the manufacturer’s instructions and cells were 
subsequently used for RNA isolation. Purity of CD31+ sorted cells was assessed by flow 
cytometry and cytospin. For cytospin, 50,000 MACS-sorted cells in 100 µl were centrifuged 
onto glass slides for 5 min at 650 rpm using a Shandon Cytospin 3 cyto-centrifuge. Total 
RNA from MACS or FACS-sorted cells was isolated using the RNeasy Plus Mini Kit (Qiagen, 
Hilden, Germany). Total RNA was eluted in RNase-free water and RNA yield was measured 
using a Nanodrop 1000 (Nanodrop, Wilmington, DE, USA) spectrophotometer and quality 
was assessed using an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). Samples 
were stored at -80 °C until further use. 
 
GeneChip microarray assay 
Sample preparation for microarray hybridization was carried out as described in the Ambion 
WT Expression Kit Protocol (Life Technologies, Carlsbad, CA, USA) and the Affymetrix WT 
Terminal Labeling and Hybridization User Manual (Affymetrix, Inc., Santa Clara, CA, USA). 
In brief, 300 ng of total RNA were used to generate double-stranded cDNA. 12 µg of 
subsequently synthesized cRNA was purified and reverse transcribed into sense-strand (ss) 
cDNA, whereat unnatural dUTP residues were incorporated. Purified ss cDNA was 
fragmented using a combination of uracil DNA glycosylase (UDG) and apurinic/apyrimidinic 
endonuclease 1 (APE 1) followed by a terminal labeling with biotin. 3,8 µg fragmented and 
labeled ss cDNA were hybridized to Affymetrix Mouse Gene 1.0 ST arrays for 16 h at 45 °C 
in a rotating chamber. Hybridized arrays were washed and stained in an Affymetrix Fluidics 
Station FS450, and the fluorescent signals were measured with an Affymetrix GeneChip 
Scanner 3000 7G. 
Sample processing was performed at an Affymetrix Service Provider and Core Facility, “KFB 
- Center of Excellence for Fluorescent Bioanalytics” (Regensburg, Germany; www.kfb-
regensburg.de). 
 
Microarray data analysis 
Summarized probe set signals were calculated by using the RMA6 algorithm with the 
Affymetrix GeneChip Expression Console Software. After exporting into Microsoft Excel, 
average signal values, comparison fold changes and significance P values were calculated 
using unequal variance Student’s t test. Probe sets with a fold change above 2.0 fold and a 
p-value lower than 0.05 were considered as significantly regulated. 
 
FACS 
For FACS analysis, a sample of each single cell suspension (200 µl) after tissue dissociation 
and before MACS analysis was transferred into round bottom FACS tubes followed by a 
washing step with 3 ml FACS buffer (PBS, 1 % BSA, 0.1 % EDTA). After centrifugation cells 
were re-suspended in 50 µl FACS buffer containing the antibody mix. For determination of 
the auto fluorescence of the cells, one sample of unstained cells was set aside and staining 
controls with respective isotypes were prepared by splitting the samples before staining. The 
FACS analyzer was calibrated using BD™Calibrite beads followed by the automated 
compensation program. To distinguish between resident microglia and invading 
macrophages, we used the markers CD11b-APC and CD45-efluor™450 for FACS analysis 
(all antibodies from eBioscience, San Diego, CA). The percentage of positive cells 
determined over 10,000 events were analyzed on a BD Biosciences LSR Fortessa 5 Laser 
analyzer and fluorescence intensity is expressed in arbitrary units on a logarithmic scale. Co-
expression of anti-mouse CD11b-APC and CD45-efluor™450 are shown in density plots. 
CD11b+CD45hi cells are infiltrating monocytes/macrophages while CD11b+CD45low are the 
intrinsic microglial population. Data are presented as mean +/- SD, n = 3. 
 
Statistical analysis 
All data are presented as scatter dot blots with mean ± standard deviation. The sex ratio was 
tested using Fisher’s exact test. All data were analyzed using unpaired two-tailed Students t-
Test. Deviation from normal distribution was checked with histograms and calculation of 
skewness. In case of an absolute value of the skewness lower one we treated the data as 
sufficiently normally distributed with regard to statistical methods which require normal 
distributed data. In case of skewness we log-transformed the data before analyses or used 
non-parametric methods. Unequal variance t-test for independent samples was used for 
gene expression analysis and if indicated (Figure 1e). Data of the extended neuroscore were 
tested using the Whitney-Mann-U-test.  
For the test of endothelial specific ablation of Stat3 we used regression analysis with robust 
variance estimates to overcome the problem of unequal variances with day, genotype and 
the interaction of both as independent variables.  
Stat3 mRNA (log-transformed) after MCAo over time in wildtype mice ipsi/contra was tested 
with a linear mixed model including interaction term for time*ipsi/contra to account for 
clustering of data within mice (random intercept model). FACS data were analyzed similarly 
with a linear mixed model using FACS as dependent variable (log-transformed) and 
genotype, CD11b+/CD45low/CD11b+/CD45high and ipsilateral/contralateral as independent 
variables. In the model we also included interaction terms for genotype*ipsi/contra and 
CD11b+/CD45low/CD11b+/CD45high*genotype. All reported p-values are derived from 
regression based post hoc tests using Bonferroni-adjustment for multiple testing. Bonferroni 
adjustment was done for post-hoc tests in a particular regression model. Otherwise no 
adjustment for multiple testing was applied since this an exploratory study.  
For testing expression levels of angiogenic or axon-modulating genes between WT and KO 
we used one sample t-test to test fold_mRNA against the hypotheses that these values are 0 
on average.  
Regression models, unequal variance t-test and one sample t-test were calculated using IBM 
SPSS 22.0. The regression model with robust variance estimates was calculated using 
STATA/IC 13.1. 
 
 
Supplemental Table 1. Gene array results of the neurovascular niche after cerebral 
ischemia 
Gene symbol Gene description 
Fold change 
Tie2-CreERT2; 
Stat3floxed/KO 
vs 
Tie2-CreERT2 
p-value  
(t-test) Gene accession 
2810055G20Rik  RIKEN cDNA 2810055G20 gene  -2.08 0.05 NR_015543  
2810417H13Rik  RIKEN cDNA 2810417H13 gene  2.00 0.01 NM_026515  
2900055J20Rik  RIKEN cDNA 2900055J20 gene  -2.22 0.05 NR_045177  
4933409K07Rik  RIKEN cDNA 4933409K07 gene  2.40 0.01 NR_033123  
6430704M03Rik  RIKEN cDNA 6430704M03 gene  -3.31 0.03 NM_001142965  
AA467197  expressed sequence AA467197  4.72 0.00 ENSMUST00000047498  
Abcg4  ATP-binding cassette, sub-family G 
(WHITE), member 4  -2.02 0.04 ENSMUST00000034648  
Adam22  a disintegrin and metallopeptidase 
domain 22  -2.77 0.04 ENSMUST00000088746  
Adam23  a disintegrin and metallopeptidase 
domain 23  -2.89 0.05 NM_011780  
Adamts9  a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin 
type 1 motif, 9  
5.02 0.00 NM_175314  
Adcy2  adenylate cyclase 2  -2.90 0.05 NM_153534  
Adcy8  adenylate cyclase 8  -2.40 0.04 NM_009623  
Adcyap1r1  adenylate cyclase activating 
polypeptide 1 receptor 1  -2.51 0.04 NM_007407  
Adora1  adenosine A1 receptor  -2.52 0.05 NM_001008533  
Agt  angiotensinogen (serpin peptidase 
inhibitor, clade A, member 8)  -3.08 0.01 NM_007428  
Agxt2l1  alanine-glyoxylate aminotransferase 2-
like 1  -2.43 0.03 NM_027907  
AI504432  expressed sequence AI504432  -2.05 0.04 NR_033498  
Akap6  A kinase (PRKA) anchor protein 6  -3.38 0.03 NM_198111  
Akr1b8  aldo-keto reductase family 1, member 
B8  2.89 0.00 NM_008012  
Amph  amphiphysin  -2.76 0.05 NM_175007  
Ank2  ankyrin 2, brain  -2.57 0.04 ENSMUST00000043741  
Ano3  anoctamin 3  -3.20 0.02 NM_001128103  
Apln  apelin  2.19 0.00 NM_013912  
Aplnr  apelin receptor  7.46 0.00 NM_011784  
Arhgap32  Rho GTPase activating protein 32  -2.13 0.02 NM_001195632  
Astn1  astrotactin 1  -3.70 0.03 NM_001205204  
Atp1a3  ATPase, Na+/K+ transporting, alpha 3 
polypeptide  -4.24 0.01 NM_144921  
B3galt2  UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 2  -3.54 0.02 NM_020025  
Bai3  brain-specific angiogenesis inhibitor 3 -4.86 0.04 ENSMUST00000151309  
Bcl6b  B cell CLL/lymphoma 6, member B  2.12 0.00 NM_007528  
Bmp2  bone morphogenetic protein 2  2.63 0.03 NM_007553  
C1ql3  C1q-like 3  -3.82 0.03 NM_153155  
Cacna2d1  calcium channel, voltage-dependent, 
alpha2/delta subunit 1  -2.45 0.04 NM_001110843  
Cacng2  calcium channel, voltage-dependent, 
gamma subunit 2  -2.02 0.03 ENSMUST00000019290  
Caln1  calneuron 1  -2.45 0.01 NM_181045  
Camk4  calcium/calmodulin-dependent protein 
kinase IV  -2.04 0.04 NM_009793  
Camta1  calmodulin binding transcription 
activator 1  -3.41 0.02 NM_001081557  
Car13  carbonic anhydrase 13  2.05 0.03 NM_024495  
Cck  cholecystokinin  -3.28 0.01 NM_031161  
Ccna2  cyclin A2  2.23 0.01 NM_009828  
Ccnb2  cyclin B2  2.08 0.01 NM_007630  
Cd14  CD14 antigen  2.12 0.00 NM_009841  
Cd36  CD36 antigen  2.47 0.00 NM_001159557  
Cda  cytidine deaminase  2.04 0.02 NM_028176  
Cdh10  cadherin 10  -3.76 0.05 NM_009865  
Cdh12  cadherin 12  -2.01 0.01 NM_001008420  
Cdh19  cadherin 19, type 2  -3.52 0.04 NM_001081386  
Cdh8  cadherin 8  -2.20 0.04 ENSMUST00000128860  
Cdh9  cadherin 9  -2.18 0.03 NM_009869  
Celsr2  cadherin, EGF LAG seven-pass G-type 
receptor 2 (flamingo homolog, 
Drosophila)  
-2.65 0.03 NM_017392  
Chga  chromogranin A  -2.95 0.01 NM_007693  
Chl1  cell adhesion molecule with homology 
to L1CAM  -2.99 0.02 NM_007697  
Chn1  chimerin (chimaerin) 1  -2.44 0.03 NM_001113246  
Chrna4  cholinergic receptor, nicotinic, alpha 
polypeptide 4  -2.64 0.00 NM_015730  
Cks2  CDC28 protein kinase regulatory 
subunit 2  2.07 0.03 NM_025415  
Clstn2  calsyntenin 2  -2.86 0.03 NM_022319  
Clstn3  calsyntenin 3  -2.83 0.03 NM_153508  
Cnih3  cornichon homolog 3 (Drosophila)  -2.08 0.01 NM_028408  
Cnksr2  connector enhancer of kinase 
suppressor of Ras 2  -5.63 0.01 NM_177751  
Csmd3  CUB and Sushi multiple domains 3  -3.70 0.02 NM_001081391  
Cyfip2  cytoplasmic FMR1 interacting protein 
2  -2.79 0.02 NM_133769  
D10Bwg1379e  DNA segment, Chr 10, Brigham & 
Women's Genetics 1379 expressed  -2.55 0.02 NM_001033258  
D17H6S56E-5  DNA segment, Chr 17, human D6S56E 
5  2.06 0.00 L78788  
D430041D05Rik  RIKEN cDNA D430041D05 gene  -2.23 0.02 NM_001033347  
Dbc1  deleted in bladder cancer 1 (human)  -2.51 0.04 NM_019967  
Dbpht2  DNA binding protein with his-thr 
domain  -2.35 0.03 NM_198866  
Dclk1  doublecortin-like kinase 1  -3.32 0.05 ENSMUST00000167204  
Diras2  DIRAS family, GTP-binding RAS-like 2  -2.35 0.04 NM_001024474  
Dnajc6  DnaJ (Hsp40) homolog, subfamily C, 
member 6  -2.82 0.04 NM_001164585  
Dner  delta/notch-like EGF-related receptor  -3.28 0.04 NM_152915  
Dock3  dedicator of cyto-kinesis 3  -3.78 0.03 NM_153413  
Dpp10  dipeptidylpeptidase 10  -2.91 0.03 NM_199021  
Dpp6  dipeptidylpeptidase 6  -2.74 0.02 NM_207282  
Edil3  EGF-like repeats and discoidin I-like 
domains 3  -4.30 0.01 NM_001037987  
Elmod1  ELMO domain containing 1  -3.82 0.02 NM_177769  
Eno2  enolase 2, gamma neuronal  -3.19 0.04 NM_013509  
Epha6  Eph receptor A6  -2.16 0.04 NM_007938  
Faim2  Fas apoptotic inhibitory molecule 2  -5.57 0.01 NM_028224  
Fam171b  family with sequence similarity 171, 
member B  -3.01 0.04 NM_175514  
Fam19a1  family with sequence similarity 19, 
member A1  -2.14 0.03 NM_182808  
Fam5c  family with sequence similarity 5, 
member C  -2.51 0.05 NM_153539  
Fat3  FAT tumor suppressor homolog 3 
(Drosophila)  -2.57 0.02 NM_001080814  
Fbxl16  F-box and leucine-rich repeat protein 
16  -2.62 0.04 NM_001164225  
Fut9  fucosyltransferase 9  -5.22 0.01 NM_010243  
Gabbr2  gamma-aminobutyric acid (GABA) B 
receptor, 2  -4.27 0.03 NM_001081141  
Gabra1  gamma-aminobutyric acid (GABA) A 
receptor, subunit alpha 1  -9.38 0.01 NM_010250  
Gabra3  gamma-aminobutyric acid (GABA) A 
receptor, subunit alpha 3  -3.34 0.03 NM_008067  
Gabra5  gamma-aminobutyric acid (GABA) A 
receptor, subunit alpha 5  -3.38 0.04 NM_176942  
Gabrb1  gamma-aminobutyric acid (GABA) A 
receptor, subunit beta 1  -3.88 0.03 ENSMUST00000031122  
Gabrb2  gamma-aminobutyric acid (GABA) A 
receptor, subunit beta 2  -8.31 0.01 NM_008070  
Gabrb3  gamma-aminobutyric acid (GABA) A 
receptor, subunit beta 3  -4.94 0.01 NM_008071  
Gabrg2  gamma-aminobutyric acid (GABA) A 
receptor, subunit gamma 2  -9.06 0.01 ENSMUST00000070725  
Gabrg3  gamma-aminobutyric acid (GABA) A -3.52 0.02 NM_008074  
receptor, subunit gamma 3 
Gad2  glutamic acid decarboxylase 2  -2.84 0.02 NM_008078  
Glrb  glycine receptor, beta subunit  -3.02 0.03 NM_010298  
Gm10419  predicted gene 10419  -2.80 0.03 AK165889  
Gm3893  predicted gene 3893  2.89 0.04 BC059060  
Gm5567  predicted gene 5567  -5.05 0.02 NM_001004182  
Gpr158  G protein-coupled receptor 158  -8.02 0.01 NM_001004761  
Gpr165  G protein-coupled receptor 165  -2.18 0.05 NM_029536  
Gpr22  G protein-coupled receptor 22  -2.15 0.01 NM_175191  
Gpr37  G protein-coupled receptor 37  -4.05 0.04 ENSMUST00000054867  
Gpr37l1  G protein-coupled receptor 37-like 1  -3.41 0.05 NM_134438  
Gria1  glutamate receptor, ionotropic, AMPA1 
(alpha 1)  -2.57 0.05 NM_001113325  
Gria3  glutamate receptor, ionotropic, AMPA3 
(alpha 3)  -4.95 0.05 NM_016886  
Grik2  glutamate receptor, ionotropic, kainate 
2 (beta 2)  -3.12 0.05 NM_010349  
Grin2b  glutamate receptor, ionotropic, 
NMDA2B (epsilon 2)  -5.52 0.01 NM_008171  
Grm1  glutamate receptor, metabotropic 1  -3.58 0.04 NM_016976  
Grm3  glutamate receptor, metabotropic 3  -3.65 0.05 NM_181850  
Grm5  glutamate receptor, metabotropic 5  -3.59 0.02 NM_001143834  
Hcn1  hyperpolarization-activated, cyclic 
nucleotide-gated K+ 1  -4.80 0.01 NM_010408  
Hmox1  heme oxygenase (decycling) 1  3.12 0.00 NM_010442  
Igsf21  immunoglobin superfamily, member 
21  -2.71 0.05 NM_198610  
Itih3  inter-alpha trypsin inhibitor, heavy 
chain 3  -2.24 0.04 NM_008407  
Kcna1  potassium voltage-gated channel, 
shaker-related subfamily, member 1  -3.70 0.03 NM_010595  
Kcna2  potassium voltage-gated channel, 
shaker-related subfamily, member 2  -2.84 0.04 NM_008417  
Kcna4  potassium voltage-gated channel, -2.21 0.03 NM_021275  
shaker-related subfamily, member 4 
Kcnd2  potassium voltage-gated channel, 
Shal-related family, member 2  -4.56 0.03 NM_019697  
Kcnh5  potassium voltage-gated channel, 
subfamily H (eag-related), member 5  -2.62 0.01 NM_172805  
Kcnh7  potassium voltage-gated channel, 
subfamily H (eag-related), member 7  -3.04 0.03 NM_133207  
Kcnip3  Kv channel interacting protein 3, 
calsenilin  -2.47 0.05 NM_019789  
Kcnip4  Kv channel interacting protein 4  -2.02 0.04 NM_001199242  
Kcnj3  potassium inwardly-rectifying channel, 
subfamily J, member 3  -2.97 0.04 ENSMUST00000067101  
Kcnma1  potassium large conductance calcium-
activated channel, subfamily M, alpha 
member 1  
-2.72 0.02 NM_001253369  
Kcnq3  potassium voltage-gated channel, 
subfamily Q, member 3  -2.15 0.01 NM_152923  
Kcnq5  potassium voltage-gated channel, 
subfamily Q, member 5  -2.16 0.05 NM_001160139  
Kcnv1  potassium channel, subfamily V, 
member 1  -2.99 0.04 NM_026200  
Kif5c  kinesin family member 5C  -2.22 0.05 NM_008449  
Kit  kit oncogene  3.91 0.00 NM_001122733  
Lamb1  laminin B1  2.23 0.02 NM_008482  
Lgi3  leucine-rich repeat LGI family, member 
3  -4.12 0.03 NM_145219  
Lmo3  LIM domain only 3  -2.59 0.02 NM_207222  
Lonrf2  LON peptidase N-terminal domain and 
ring finger 2  -3.42 0.04 ENSMUST00000147695  
Lphn1  latrophilin 1  -2.18 0.03 NM_181039  
Lrg1  leucine-rich alpha-2-glycoprotein 1  2.23 0.04 NM_029796  
Lrp1b  low density lipoprotein-related protein 
1B (deleted in tumors)  -2.44 0.04 NM_053011  
Lrrc4c  leucine rich repeat containing 4C  -4.04 0.02 NM_178725  
Lrrn1  leucine rich repeat protein 1, neuronal  -4.15 0.04 NM_008516  
Lrrtm2  leucine rich repeat transmembrane 
neuronal 2  -2.99 0.03 NM_178005  
Lrrtm3  leucine rich repeat transmembrane 
neuronal 3  -3.89 0.02 NM_178678  
Lrrtm4  leucine rich repeat transmembrane 
neuronal 4  -2.17 0.03 NR_027323  
Mal2  mal, T cell differentiation protein 2  -3.73 0.03 NM_178920  
Mapk10  mitogen-activated protein kinase 10  -3.36 0.02 NM_009158  
Mapk8ip2  mitogen-activated protein kinase 8 
interacting protein 2  -2.15 0.04 ENSMUST00000023291  
Mdga2  MAM domain containing 
glycosylphosphatidylinositol anchor 2 -2.91 0.03 NM_001193266  
Mgat4c  mannosyl (alpha-1,3-)-glycoprotein 
beta-1,4-N-
acetylglucosaminyltransferase, 
isozyme C (putative)  
-2.18 0.02 NM_001162369  
Mtap2  microtubule-associated protein 2  -2.21 0.03 NM_001039934  
Nalcn  sodium leak channel, non-selective  -2.02 0.02 NM_177393  
Napb  N-ethylmaleimide sensitive fusion 
protein attachment protein beta  -2.58 0.02 ENSMUST00000028926  
Ncam1  neural cell adhesion molecule 1  -3.53 0.02 NM_001081445  
Ncam2  neural cell adhesion molecule 2  -3.93 0.03 NM_001113208  
Ndst4  N-deacetylase/N-sulfotransferase 
(heparin glucosaminyl) 4  -2.63 0.01 NM_022565  
Necab1  N-terminal EF-hand calcium binding 
protein 1  -3.82 0.01 NM_178617  
Nell2  NEL-like 2 (chicken)  -4.15 0.03 NM_016743  
Neto2  neuropilin (NRP) and tolloid (TLL)-like 
2  -2.10 0.04 NM_001081324  
Nkain2  Na+/K+ transporting ATPase 
interacting 2  -3.87 0.02 NM_001013411  
Nlgn1  neuroligin 1  -2.96 0.05 NM_138666  
Nlgn3  neuroligin 3  -3.08 0.02 NM_172932  
Nos2 nitric oxide synthase 2, inducible 1.47 0.04 ENSMUST00000018610 
Nova1  neuro-oncological ventral antigen 1  -4.15 0.04 NM_021361  
Nox4 NADPH oxidase 4 1.90 0.01 ENSMUST00000032781 
Nrcam  neuron-glia-CAM-related cell adhesion 
molecule  -3.10 0.01 NM_176930  
Nrxn1  neurexin I  -3.87 0.03 NM_020252  
Ntm  neurotrimin  -2.46 0.04 NM_172290  
Ntrk3  neurotrophic tyrosine kinase, receptor, 
type 3  -2.21 0.05 ENSMUST00000039431  
Nxph1  neurexophilin 1  -2.01 0.05 ENSMUST00000060369  
Odz1  odd Oz/ten-m homolog 1 (Drosophila)  -2.51 0.02 NM_011855  
Odz2  odd Oz/ten-m homolog 2 (Drosophila)  -2.07 0.04 NM_011856  
Odz3  odd Oz/ten-m homolog 3 (Drosophila)  -3.40 0.02 NM_011857  
Olfm1  olfactomedin 1  -2.00 0.02 NM_019498  
Olfm3  olfactomedin 3  -2.39 0.04 NM_153157  
Opcml  opioid binding protein/cell adhesion 
molecule-like  -4.39 0.02 NM_177906  
Pak3  p21 protein (Cdc42/Rac)-activated 
kinase 3  -2.46 0.03 ENSMUST00000112863  
Pcdh10  protocadherin 10  -3.69 0.04 NM_001098171  
Pcdh9  protocadherin 9  -4.53 0.02 NM_001081377  
Pclo  piccolo (presynaptic cytomatrix 
protein)  -2.41 0.02 NM_001110796  
Pdlim1  PDZ and LIM domain 1 (elfin)  4.07 0.01 NM_016861  
Pgf  placental growth factor  4.11 0.00 NM_008827  
Pnmal2  PNMA-like 2  -2.08 0.05 NM_001099636  
Prg4  proteoglycan 4 (megakaryocyte 
stimulating factor, articular superficial 
zone protein)  
2.38 0.00 NM_021400  
Prkca  protein kinase C, alpha  -2.09 0.05 NM_011101  
Prkcg  protein kinase C, gamma  -2.55 0.04 NM_011102  
Prnd  prion protein dublet  5.95 0.01 NM_023043  
Ptk2b  PTK2 protein tyrosine kinase 2 beta  -2.18 0.04 NM_001162365  
Ptprn  protein tyrosine phosphatase, receptor 
type, N  -2.54 0.04 NM_008985  
Ptprn2  protein tyrosine phosphatase, receptor 
type, N polypeptide 2  -2.07 0.04 NM_011215  
Ptprt  protein tyrosine phosphatase, receptor 
type, T  -2.23 0.05 NM_021464  
Ptprz1  protein tyrosine phosphatase, receptor 
type Z, polypeptide 1  -3.91 0.05 NM_001081306  
Pxdn  peroxidasin homolog (Drosophila)  3.24 0.00 NM_181395  
Raet1d  // Raet1b  
// Raet1a  
retinoic acid early transcript delta  // 
retinoic acid early transcript beta  // 
retinoic acid early transcript 1, alpha  
2.60 0.01 ENSMUST00000130977 
Raet1e  // Raet1c  retinoic acid early transcript 1E  // 
retinoic acid early transcript gamma  2.29 0.02 ENSMUST00000065527 
Rasgrp1  RAS guanyl releasing protein 1  -6.40 0.01 NM_011246  
Reln  reelin  -3.65 0.00 NM_011261  
Robo2  roundabout homolog 2 (Drosophila)  -2.53 0.01 NM_175549  
Rtn1  reticulon 1  -4.01 0.02 NM_153457  
Scn1a  sodium channel, voltage-gated, type I, 
alpha  -2.06 0.00 NM_018733  
Scn2a1  sodium channel, voltage-gated, type II, 
alpha 1  -8.76 0.01 NM_001099298  
Sele  selectin, endothelial cell  2.19 0.01 NM_011345  
Selp  selectin, platelet  5.70 0.01 NM_011347  
Serpine1  serine (or cysteine) peptidase 
inhibitor, clade E, member 1  5.44 0.00 NM_008871  
Sez6l2  seizure related 6 homolog like 2  -4.26 0.03 NM_144926  
Sfrp4  secreted frizzled-related protein 4  2.85 0.01 ENSMUST00000169327  
Slc17a7  solute carrier family 17 (sodium-
dependent inorganic phosphate 
cotransporter), member 7  
-6.75 0.02 NM_182993  
Slc24a2  solute carrier family 24 
(sodium/potassium/calcium 
exchanger), member 2  
-5.78 0.01 NM_172426  
Slc2a13  solute carrier family 2 (facilitated 
glucose transporter), member 13  -2.82 0.01 NM_001033633  
Slc6a1  solute carrier family 6 
(neurotransmitter transporter, GABA), 
member 1  
-4.18 0.04 NM_178703  
Slc6a11  solute carrier family 6 
(neurotransmitter transporter, GABA), 
member 11  
-5.60 0.01 NM_172890  
Slc6a9  solute carrier family 6 
(neurotransmitter transporter, glycine), 
member 9  
-2.42 0.04 ENSMUST00000063857  
Slc7a14  solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 
14  
-4.34 0.00 NM_172861  
Slc8a1  solute carrier family 8 (sodium/calcium 
exchanger), member 1  -5.23 0.00 NM_011406  
Slco2a1  solute carrier organic anion 
transporter family, member 2a1  2.40 0.03 NM_033314  
Slitrk1  SLIT and NTRK-like family, member 1  -2.32 0.05 NM_199065  
Slitrk3  SLIT and NTRK-like family, member 3  -3.95 0.03 NM_198864  
Slitrk4  SLIT and NTRK-like family, member 4  -2.09 0.01 NM_178740  
Snap25  synaptosomal-associated protein 25  -4.33 0.02 NM_011428  
Snora31  small nucleolar RNA, H/ACA box 31  3.74 0.04 NR_028481  
Snora33  small nucleolar RNA, H/ACA box 33  6.13 0.04 NR_037680  
Snora44  small nucleolar RNA, H/ACA box 44  2.09 0.02 NR_034050  
Snora73b  small nucleolar RNA, H/ACA box 73b  2.12 0.04 NR_028513  
Sorcs1  VPS10 domain receptor protein 
SORCS 1  -2.01 0.03 NM_021377  
Sorcs3  sortilin-related VPS10 domain 
containing receptor 3  -2.54 0.03 NM_025696  
Sorl1  sortilin-related receptor, LDLR class A 
repeats-containing  -2.88 0.03 NM_011436  
Sphkap  SPHK1 interactor, AKAP domain 
containing  -2.87 0.01 ENSMUST00000160953  
Spock1  sparc/osteonectin, cwcv and kazal-like 
domains proteoglycan 1  -2.66 0.03 NM_009262  
Spon1  spondin 1, (f-spondin) extracellular 
matrix protein  -2.41 0.03 NM_145584  
Sprn  shadow of prion protein  -2.14 0.05 NM_183147  
Srgap3  SLIT-ROBO Rho GTPase activating 
protein 3  -2.38 0.05 NM_080448  
Sstr2  somatostatin receptor 2  -2.04 0.03 NM_009217  
St6gal2  beta galactoside alpha 2,6 
sialyltransferase 2  -4.81 0.01 NM_172829  
St8sia5  ST8 alpha-N-acetyl-neuraminide alpha-
2,8-sialyltransferase 5  -3.69 0.01 NM_013666  
Stxbp5l  syntaxin binding protein 5-like  -3.68 0.03 NM_172440  
Sv2a  synaptic vesicle glycoprotein 2 a  -3.60 0.04 NM_022030  
Sv2b  synaptic vesicle glycoprotein 2 b  -11.75 0.00 NM_001109753  
Syn1  synapsin I  -3.14 0.03 NM_013680  
Syn2  synapsin II  -2.32 0.03 NM_001111015  
Syngr3  synaptogyrin 3  -2.21 0.04 NM_011522  
Syp  synaptophysin  -3.29 0.04 NM_009305  
Syt1  synaptotagmin I  -9.31 0.02 NM_001252341  
Syt5  synaptotagmin V  -3.15 0.02 NM_016908  
Tbr1  T-box brain gene 1  -3.06 0.02 NM_009322  
Thbs1  thrombospondin 1  2.02 0.00 NM_011580  
Timp1  tissue inhibitor of metalloproteinase 1  2.51 0.00 NM_001044384  
Tmem130  transmembrane protein 130  -4.09 0.01 NM_177735  
Tmem56  transmembrane protein 56  -2.62 0.02 ENSMUST00000029777  
Tmem59l  transmembrane protein 59-like  -2.35 0.02 NM_182991  
Tnfrsf23  tumor necrosis factor receptor 
superfamily, member 23  2.12 0.02 NM_024290  
Tnr  tenascin R  -4.80 0.03 NM_022312  
Trim2  tripartite motif-containing 2  -2.20 0.05 ENSMUST00000107691  
Trp53i11  transformation related protein 53 
inducible protein 11  2.21 0.00 NM_001025246  
Tubb6  tubulin, beta 6 class V  2.80 0.00 NM_026473  
Ube2ql1  ubiquitin-conjugating enzyme E2Q 
family-like 1  -3.38 0.04 NM_001145162  
Unc5a  unc-5 homolog A (C. elegans)  -2.31 0.04 ENSMUST00000026994  
Upp1  uridine phosphorylase 1  2.77 0.02 NM_009477  
Vsig4  V-set and immunoglobulin domain 
containing 4  2.43 0.00 NM_177789  
Vsnl1  visinin-like 1  -5.67 0.01 NM_012038  
Vstm2a  V-set and transmembrane domain 
containing 2A  -3.20 0.02 NM_145967  
Xylt1  xylosyltransferase 1  -2.15 0.05 NM_175645  
Supplemental Figure 
 
 
Supplemental Figure 1. Endothelial Stat3 has no impact on systemic Il6 and Vegf 
serum levels after cerebral ischemia. Serum levels of Il6 (A) were determined at 2 days 
and 28 days after cerebral ischemia. Data are presented as scatter dot blots with mean ± s.d. 
Two way ANOVA was followed by Tukey’s posthoc analysis with F(1,36) = 8.6 for reperfusion 
time point with p = 0.006. There was no significant difference between genotypes with 
F(1,36) = 0.08 and p = 0.78. *p = 0.02 versus corresponding 2 days reperfusion time points 
within the same genotype group. Serum levels of Vegf (B) were determined 2 days and 28 
days after cerebral ischemia. Data are presented as scatter dot blots with mean ± s.d. Two 
way ANOVA was followed by Tukey’s posthoc analysis with F(1,40) = 94.4 for reperfusion time 
point with p < 0.001. There was no significant difference between genotypes with F(1,40) = 0.5 
and p = 0.51. ***p < 0.001 versus corresponding 2 days reperfusion time points within the 
same genotype group. 
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Supplemental video legend 
Supplemental movie 1. Post-ischemic angiogenesis is reduced after endothelial-
specific ablation of Stat3. Tie2-CreERT2 littermates (n=11) and Tie2-CreERT2;Stat3floxed/KO 
(n=7) were subjected to 30 min MCAo after 5 days of daily tamoxifen administration followed 
by a free interval of 2 days and were killed 28 days after cerebral ischemia and stained for 
caveolin-1. Confocal images of isolectin B4 stained vascular networks were collected with a 
spinning disc system consisting of a Axio Observer Z.1 microscope (Zeiss, Jena, Germany) 
equipped with a Yokogawa CSU-X1 unit using a 20x/0.4 Korr M27 objective and processed 
with ZEN2012 software (Zeiss, Jena, Germany). Orthogonal projections (60 µm) and 
supplementary movie were generated by ImageJ. 3D projections of peri-infarct vascular 
networks. 
 
